Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGELLAN-AMD phase 3 trial of FYB203 versus Eylea in neovascular age-related macular degeneration
MOH_2021-09-01_010234Phase 3Not yet recruiting
- Sponsor
- Bioeq AG
- Start
- Aug 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing FYB203 with Eylea (2 arms). Primary endpoint: Change from baseline in best-corrected visual acuity at Week 8. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
baiamaaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-09-01_010234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-01_010234.